Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis

Wytske Fokkens, Rik van der Lans, Sietze Reitsma

Research output: Contribution to journalArticleAcademicpeer-review

13 Citations (Scopus)

Abstract

Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) affects 1–2.5% of the population and is associated with significant adverse effects on quality of life (QoL). CRSwNP is strongly correlated with (late onset) asthma with 30–70% of the CRSwNP patients having asthma. Health-care spending in rhinosinusitis is high, especially because of indirect costs. Areas covered: In the last years, the recognition of endotyping as an essential presumption to precision medicine has significantly changed the integrated care pathways in the treatment of chronic rhinosinusitis. Dupilumab is the first biological available for the treatment of CRswNP, since late 2019. Treatment with dupilumab results in a significant improvement of QoL (measured as SNOT-22), rhinosinusitis disease severity, symptoms of rhinosinusitis, and especially sense of smell, nasal polyp score, Lund-Mackay CT score, and asthma outcomes (ACQ5 and FEV1) compared to placebo. Expert opinion: At this moment, the high cost of the treatment requires careful patient selection and within the EUFOREA and EPOS2020 context, experts have tried to give guidance based on today’s data. We now need trials evaluating which patients benefit most from treatment with biologicals and in which patients the treatment is cost-effective.
Original languageEnglish
Pages (from-to)575-585
Number of pages11
JournalExpert Opinion on Biological Therapy
Volume21
Issue number5
Early online date2021
DOIs
Publication statusPublished - 2021

Keywords

  • Chronic rhinosinusitis
  • EPOS2020
  • biological
  • dupilumab
  • nasal polyps

Cite this